Electromedical Technologies Inc (OTCMKTS:EMED) may be the most interesting player in the emerging space of bioelectronic medicine – a field that has recently spurred a number of major media pieces covering what appears to be a legitimate revolution in the health treatment space.
The field, itself, is really starting to pick up steam as far as general cultural acceptance, with recent major coverage in Time Magazine, CNN, NBC, and other major outlets.
The core medical establishment is starting to come around as well, with a number of key peer-reviewed journals featuring breakthrough research supporting the paradigm as well.
The big revelation here is about how the body is, ultimately, managed by an electro-chemical systemic operating system. Everything can be reduced to electrons at the end of the day. And cellular biology is no different. It all rests on a delicate balance of electrical activity patterns.
The important contrast here is well highlighted by thinking in terms of solutions for chronic pain. The standard of care right now is opioid drugs. But the addition epidemic surrounding that toolset is well understood. Over a hundred people die every single day in the US from overdosing on opioid painkillers. That’s unacceptable.
Bioelectronic medicine offers a different, and well-established, path to solving that same problem without the addiction and overdose epidemic.
In addition to solving chronic pain, Electromedical Technologies Inc (OTCMKTS:EMED) is developing a wider research and development framework for expanding the applications of its technology.
As a case in point, the company recently announced the launch of a Phase 1 research program in collaboration with Nazarbayev University to identify the most effective electrical frequencies for driving physiological responses in animal models.
Matthew Wolfson, Founder and CEO of Electromedical Technologies, explained, “We will be tapping into the revolutionary potential of electro-modulation with this Phase 1 study. The core objective is deciphering the physiological impact of a wide range of electrical frequencies in animal models. Explicit animal research will be instrumental in validating effective electrical frequencies. Our unique research program will establish a platform for enhancing electro-modulation.”
This move will function to create a foundation of further credibility for EMED as it seeks to expand its overall treatment footprint.
As noted in the release, its investment in this animal research program is meant to advance the science of electro-modulation and accelerate the development of its applications in healthcare. Building a strong scientific foundation today will enable powerful advances in the technology of electro-modulation in the near future.
According to the release, the Company’s research team is being led by Professor Dos D. Sarbassov, a renowned expert in cell signaling with intensive postdoctoral research training at the Whitehead Institute for Biomedical Research (MIT).
Dr. Sarbassov, as noted, also worked for many years as Faculty of the Molecular and Cellular Oncology Department at MD Anderson Cancer Center (widely viewed one of the foremost oncology centers in the US).
In fact, in 2019, Dr. Sarbassov joined Nazarbayev University to develop a cutting-edge biomedical research program.
“Our studies of electro-modulation are in a process of transition from a simplified cell culture to the animal model system,” commented Dr. Sarbassov. “A key question is to determine if changes in cell signaling induced by specific alternating electrical fields will be sufficient to lead to physiological changes in organism. We will study effects of electro-modulation on the insulin-dependent glucose uptake, pro-inflammatory or stress-dependent cytokine secretion, hypertension, tumor growth and viral infection in mammalian animal models. Regulation of the physiological responses by electro-modulation will provide a leverage for corrections of disease related physiological defects. The proposed Stage I studies in the animal models will place a foundation for clinical applications of electro-modulation in the Stage II of our research and development program in collaboration with Electromedical Technologies. Our research work by opening the door for electro-modulation in healthcare will contribute substantially to a precision medicine of tomorrow.”
COMPENSATION DISCLOSURE: Section 17(b) of the 1933 Act requires publishers to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b): Tiger Global Management Partners LLC has compensated a third party to produce and present weekly content for various companies for the publication. For more information, please click here. In addition, this article is part of JournalTranscript.com Networks. Read the JournalTranscript.com Networks Disclaimer.